Receipt of prior radiotherapy or condition for any reason that would contribute radiation dose that would exceed tolerance of normal tissues, at the discretion of the treating physician
Must be capable of performing the exercise intervention at the time of baseline assessment as determined by the treating physician
Patients must have dermatology exam obtained within 28 days prior to registration to obtain baseline measurement; exam to be performed by treating physician or designated dermatologist
Patients must have a life expectancy of >= 12 weeks as determined clinically by the treating physician
No evidence of residual involved lymph node disease or metastatic disease at the time of registration based on clinician assessment of imaging; the treating physician will determine if incidental lesions on imaging require workup to exclude metastatic disease; if based on review of images, the treating physician determines the patient to be stage III, then the patient is eligible
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment
Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g. elevated troponin or creatinine, uncontrolled diabetes)
Total bilirubin =< 1.5 x ULN; or =< 2 x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF)
Patients whose screening MRI scan demonstrates intratumoral hemorrhage or peritumoral hemorrhage are not eligible for treatment if deemed significant by the treating physician
Transplant eligible (as determined by referring physician) patients who have failed one prior salvage therapy or transplant ineligible (as determined by referring physician) patients who have failed one prior therapy
Candidate for potentially radical, maximal effort cytoreductive surgery at the discretion and expertise of the treating physician
Patients must have recovered from the effects of any prior chemotherapy, as determined by the treating physician and study team, based in part on organ function defined above
Any other intercurrent medical/psychological problem deemed exclusionary by the treating physician or investigators/principal investigator (PI)
Patients who cannot participate in contributing to the neurocognitive outcomes due to severe neurologic impairment or language barrier will be enrolled at the discretion of the treating physician in consultation with the principal investigator (PI)
Any other factors, including psychiatric or social, that in the opinion of the treating physician makes the patient an inappropriate candidate for a study
Tumor accessible for unrestricted illumination for photodynamic therapy (PDT) (accessibility as determined by the physician)
At least one tumor lesion with location accessible to biopsy per clinical judgment of the treating physician
Diagnosis of VTE <= 30 days prior to study enrollment for which potential benefits of anticoagulation therapy to prevent recurrence of VTE are felt by the treating physician to exceed the potential harms
Treating physician intends to put participant on anticoagulation therapy for at least three months.
Note: (supportive transfusions will be allowed during treatment as deemed necessary by the treating physician)
Male patients must use a form of barrier pregnancy prevention approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation (site-specific criteria applying to Avera only)
Patients must be willing to use brief courses (at least 72 hours) of steroids as directed for potential inflammatory side effects of the therapy if recommended by their treating physician
Any other intercurrent medical/psychological problem deemed exclusionary by the treating physician or investigators/principal investigator (PI)
Untreated symptomatic hydrocephalus determined by treating physician.
Subjects must have adequate hepatic, renal, and bone marrow function. There are no specific minimum criteria for enrollment; this will at the discretion of the treating physician, as any patient who would be considered for standard of care treatment with these drugs may be considered for this trial
Active and uncontrolled disease/infection as judged by the treating physician
Severe symptomatic depression and or anxiety (study physician discretion)
Active and uncontrolled disease/infection as judged by the treating physician
Life expectancy >= 12 weeks as judged by the treating physician.
Patients with higher risk of bleeding (deemed by the treating physician) or on anticoagulation
Patients must be considered transplant eligible by the treating physician at time of study entry.
Medical condition including but not limited to ongoing or active infection or connective tissue disease (e.g. systemic sclerosis or other collagen vascular diseases) that would, in the opinion of the treating physician, make this protocol unreasonably hazardous to the patient
Patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening
Have absence of metastatic disease as determined by conventional imaging studies and be considered a good surgical candidate by the treating physician.
Rapidly progressive relapse requiring urgent chemotherapy as determined by treating physician
Deemed eligible for additional partial resection by treating physician and determined to be safe to receive 3 months of neoadjuvant therapy before planned surgery
Patients older than 65 who are deemed fit to receive intensive chemotherapy by the treating physician will be eligible after discussion with the principal investigator (PI).
Life expectancy of over 3 months as determined by treating physician
Patients must have surgically resectable disease in the opinion of the treating physician. For patients with a primary OPSCC, patients must be eligible for TORS (transoral robotic surgery)
Appropriate for treatment with sunitinib in the opinion of the treating physician
Able to walk and jog on a treadmill, in the opinion of the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Untreated symptomatic hydrocephalus determined by treating physician
Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
Must be fit enough to receive next-line chemotherapy (either gemcitabine, docetaxel, or pemetrexed [non-squamous only]) according to the discretion of the treating physician
Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
Myeloma Frailty Score:\r\n*NOTE: this will include calculating a frailty score (based on age, activities of daily living, instrumental activities of daily living and Charlson comorbidity index)\r\n** Phase I: “intermediate fitness” or “frail”; NOTE: no “fit” patients will be included in the phase 1 portion of the trial which is being done to determine the MTD of the 3-drug combination\r\n** Phase II: transplant-ineligible as per their treating physician; NOTE: all the patients with “intermediate fitness” or “frail” status will be considered transplant-ineligible; other reasons to consider transplant ineligibility may include, but are not limited to: financial constraints or patient preference; in case such patients have a frailty score of “fit”, it should be duly noted by the treating physician
Patients with a history of major psychiatric illness must be judged (by the treating physician) able to fully understand the investigational nature of the study and the risks associated with the therapy
Patients with significant malabsorption as determined by the treating physician
Any other medical or surgical condition or disease that, in the judgment of the treating physician, renders subject ineligible for high dose interleukin-2 therapy
Candidate for definitive cancer surgery as determined by treating physician
Post-operative complications including significant neurological decline or hemorrhage that causes a drop in Karnofsky performance status (KPS) to less than 60 or renders the patient not suitable for chemoradiation as determined by their treating physician
Pulmonary function test is required, within 3 months of start; the treating physician will assess suitability by usual clinical criteria used for IL-2 treatment generally consistent with the Proleukin prescribing information; there is no specific minimum result specified by the protocol
Patients who, in the estimation of the treating physician or primary investigator, have had a clinical deterioration of their ECOG performance within the month prior to enrollment
Patient with other co-morbidities that in the opinion of the treating physician would be a contra-indication to protocol participation (e.g. inflammatory bowel disease)
No active or co-existing malignancy with life expectancy less than 12 months, sources for the determination of clinical significance by the treating physician will be included in the subject’s medical record
Active and uncontrolled disease/infection as judged by the treating physician, sources for the determination of clinical significance by the treating physician will be included in the subject’s medical record
History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.
Uncontrolled disease/infection as judged by the treating physician
Psychiatric disorder which, per treating physician discretion, may preclude compliance
Life expectancy >= 10 years (as determined by the treating physician)
The risk of disease recurrence with a five (5) year time period, as estimated by the treating physician, must be greater than or equal thirty percent (30%)
Any patient with metastatic esophageal cancer that is deemed a candidate for brachytherapy for local control or treatment of dysphagia as determined by treating physician
Presence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for esophageal cancer as determined by the treating physician
Willingness to provide newly obtained tumor tissue at baseline and on treatment unless contraindicated by medical risk in the opinion of the treating physician.
Recommendation to undergo concurrent CRT, as determined by the treating physician, with a curative goal
Neurological and functional examination within 24 hours prior to registration by the treating physician
Subject would not benefit from additional cytotoxic chemotherapy as determined by the treating physician
Individuals who would benefit from additional cytotoxic chemotherapy as determined by the treating physician
Any other issue which, in the opinion of the treating physician, would make the patient ineligible for the study
Patients older than 60 who are deemed fit to receive intensive chemotherapy by the treating physician are eligible after discussion with the principal investigator (PI)
No dexamethasone use (or any other corticosteroid use with the purpose of treating cerebral edema) starting 5 days prior to the treatment planning MRI; patients may be tapered to meet this criterion if deemed safe by the treating physician
Deemed by the treating physician to be unable to eat regular meals
Active and uncontrolled disease/infection as judged by the treating physician
Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol
Patient will be approached for enrolling in the study by the PI, treating physician or a designee; informed consent will be obtained by the PI, co-investigator (co-I) or a qualified designee
Physician recruitment will consist of surveying the physicians involved in treating patients on this pilot study; physician participation will be voluntary; physicians will indicate their consent through completion of the survey; survey instructions will include information about the voluntary nature of participation, confidentiality of responses and the minimal risk related to involvement
Patient deemed eligible for rectal spacer (Space OAR) placement by treating physician
Patients may not have impending organ compromise from disease as assessed by their treating physician
other malignancies curatively treated with no evidence of disease for ? 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
Repeat radiation in fields previously radiated will be allowed at the discretion of the treating physician
History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician
Patients must be anticipated to complete 2 cycles of therapy in the opinion of the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Conditions leading to inadequate gastrointestinal tract absorption as determined by the treating physician and/or investigator
Any known contra-indication to chemoembolization according to the treating physician
Bisphosphonates are allowed, at the treating investigator’s discretion
Breasts technically unsatisfactory for radiation treatment upon the discretion of the treating physician.
Direct bilirubin equal to or less than 1.5 x ULN; or equal to or less than 2 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis related to MF)
Suitability for concurrent chemoradiation therapy per treating physician's assessment
Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol
Patient must otherwise be a candidate for ASCT as determined by the treating physician
Untreated symptomatic hydrocephalus determined by treating physician
Prophylactic use of lamivudine in patients that have antibody positive (+), but no active infection will be up to the treating physician
Temozolomide re-treatment is planned by the treating neuro-oncologist
History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician
History of clinically significant (as determined by the treating physician) atrial arrhythmia;
All subjects must have history of histologically confirmed malignancy; brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physician
Weight loss > 10 percent within 6 months prior to starting treatment that is determined by the investigator or treating physician to be directly related to tumor and not directly related local esophageal symptoms (e.g. dysphagia, odynophagia)
Patient must require treatment for symptomatic B-CLL as defined by the by the IWCLL/Hallek, December 2008 criterion or as determined clinically necessary by the treating physician
The Target Lesion must be determined to be amenable to percutaneous injection by the treating physician.
Life expectancy of >= 10 years as determined by treating physician
Tamoxifen, Arimidex or other hormonal therapy is allowed; it may begin any time relative to the radiation at the discretion of the treating physician
Patients with rapid decline in neurological function as documented on exam and/or as per clinical judgment of treating physician (Cohort D)
Must have had all standard approved and unapproved therapies as deemed appropriate by the treating physician.
Active bleeding diatheses which in the opinion of the treating physician poses a significantly increased operative risk.
Presence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for disease under treatment as determined by the treating physician
Subject’s current disease state must be one for which there is no known curative therapy, or in the case of a new diagnosis there must be ? 15% chance of cure if given standard-of-care chemotherapy (prognosis to be determined at the discretion of the treating physician)
Known active malignancy as determined by treating medical and radiation oncologist.
Other inherited metabolic disorders\r\n* Any other inherited metabolic disorder for which alloHCT is indicated and for whom, in the opinion of the treating physician, the patient’s best treatment option is with a haploidentical donor following non-myeloablative conditioning
Disease course appropriate for therapy initiation approximately 8-12 weeks from enrollment per treating physician.
Subjects must have received at least one line of chemotherapy prior to receiving adoptive T cell therapy and should have exhausted standard of care systemic therapy options; the decision to implement the T cell therapy will be at the discretion of the treating physician; the timing and total exposure to chemotherapy will depend on the tumor type in question (more systemic options for breast cancer; fewer for gastric cancer, for example); due to the heterogeneity of tumors being treated in this protocol, the discretion of the treating physician in terms of timing of immunotherapy will be critical
Life expectancy of > 5 years per the clinical impression of the treating physician(s)
Serious medical illness that in the judgment of the treating physician places the patient at high risk of operative mortality
Progression of disease on the most recent restaging scan or clinically significant disease at the time of evaluation justifying enrolment in a trial in the opinion of the treating physician
Medical oncologist or consenting physician verifies that chemotherapy options exist after treatment with intracranial therapy, and that chemotherapy is planned to initiate after completion of radiation; or, survival as estimated by the medical oncologist or enrolling physician is > 3 months
Any of the dosimetric treatment criteria as defined have not been met; patients who become ineligible due to inability to meet dosimetric criteria should not receive treatment as defined in this protocol and will come off the study; any subsequent adjuvant radiation will be delivered at the discretion of the treating physician
Patient’s comprehensive metabolic panel (CMP) must be done no more than 6 weeks prior to informed consent and the CMP levels must be within acceptable institutional limits or to the discretion of the treating physician, which may be the principal investigator of the study
Absence of clinically relevant liver or kidney failure as deemed by the treating physician
Patients must be candidates for PD-L1 antibody (Ab) as determined by the treating physician
Patients must be candidates for ipilimumab as determined by the treating physician
No gastro-intestinal condition, that in the opinion of the treating physician or the principal investigator significantly limits oral absorption
Patients must have, in the opinion of a treating physician, tumor that is accessible to biopsy in the clinic
The following pre-study tests should be obtained within 14 days prior to registration in accordance with good medical practice; results of these tests do not determine eligibility and minor deviations are acceptable if they do not impact patient safety in the judgment of the treating physician:
Patients will be limited to:\r\n* >= 70 years of age, OR\r\n* With co-morbidities that preclude treatment with standard platinum-based chemotherapy, as determined by the treating physician, OR\r\n* Karnofsky performance scale (KPS) =< 80, OR\r\n* Creatinine clearance < 30 cc/min
Patients must have recovered from prior surgery based on treating physician's discretion
Patients with severe hepatic sinusoidal obstruction syndrome who in the judgment of the treating physician are not expected to have normalized bilirubin by Day 56 after enrollment.
Physician report/letter
The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of drugs in this protocol or place the subject at undue risk for treatment complications
Not a candidate for chemotherapy as determined by the treating physician
For the most recently received VEGFR-targeting TKI there must have been progression of disease as determined by the treating physician either (i) during treatment or (ii) within 6 mo following completion of at least 4 weeks of treatment with the TKI
Patient must be appropriate for reduced intensity regimen, according to the treating physician
Patients with an active, uncontrolled systemic infection are not eligible until deemed controlled by the treating physician
Treatment with weekly single-agent paclitaxel is appropriate in the opinion of the treating physician
NOTE: Results of the bone marrow biopsy and aspirate as well as cytogenetics are mandatory to register subjects onto study, which are indispensable to determine International Prognostic Scoring System (IPSS) category needed for eligibility; please note that it is not necessary to wait for the week 16, week 32, or week bone marrow and cytogenetic results prior to starting the next cycle unless deemed necessary by the treating physician; one example of this exception can include if the subject shows signs of progression, such as increased peripheral blood blast percentage; at that juncture, the treating physician may prefer to await the results prior to starting a new cycle; if a cycle is started, and based on the bone marrow results it is felt by the treating physician that the subject should not continue on treatment, please be sure to note this information on the case report forms at end of treatment
Cancer must be considered incurable by the treating clinician
Direct bilirubin ? 1.5 x ULN; or ? 2x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
Previously treated with ruxolitinib (unless not a good candidate for ruxolitinib therapy in the judgment of treating physician)
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment
Patients must have a histologically confirmed or highly suspected (as determined by treating physician) solid tumor that is planned for surgical resection
Patients with significant malabsorption as determined by the treating physician
Good candidate for treatment per protocol in the judgement of the principle investigator (PI) and/or treating physician follow stimulation
Partial mastectomy so extensive that the cosmetic result is fair or poor prior to HG-PBI as determined by the treating physician
Uncontrolled undercurrent illness that in the opinion of the treating physician would contraindicate the use of the drug
Patient must not have obvious clinical progression of lymphoma after PBSCT as determined by the treating physician; NOTE: Restaging imaging studies are NOT required for eligibility if there is no clinical suspicion of progressive disease
History of intratumoral or peritumoral hemorrhage if deemed significant by the treating physician
Positive stool guaiac, excluding hemorrhoids or documented radiation-induced proctitis, if test is performed at the discretion of the treating physician (stool guaiac test is not required to screen for eligibility)
Physician recommendation of mucosal radiation
Active and uncontrolled disease/infection that in the opinion of the treating physician and principal investigator may affect the ability to participate in the trial or put the patient at unduly high risk
Currently enrolled in study 2007-0169 and benefiting from therapy as determined by treating physician
Patients with concomitant medical illness such as serious uncontrolled infection, or uncontrolled angina, which in the opinion of the treating physician, make the treatments prescribed on this study unreasonably hazardous for the patient
Non-CNS progression of disease as assessed by the investigator/treating physician, for which a change in systemic therapy is planned OR achievement of stable or responsive non-CNS disease for which a holiday from the current systemic therapy is planned, as assessed by the investigator/treating physician
Appropriate candidate for systemic immune-chemotherapy such as the standard rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (RCHOP)21 6 cycles as determined by the treating physician
Active collagen-vascular disease that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient
Patients on anticonvulsant therapy may continue these at the discretion of their treating physician; however, it is recommended that anticonvulsant levels be checked periodically as clinically indicated if possible
The patient is deemed by their treating physician to be at low risk of recurrence from previous malignancies.
Any condition that, in the opinion of the treating physician, would exclude the subject from receiving bevacizumab. Examples may include but are not limited to:
Willingness to undergo core biopsies at baseline and mid-cycle 1 unless contraindicated by medical risk in the opinion of the treating physician and discussed with the principal investigator
Prior radiation therapy that at the treating physician's discretion makes SABR unsafe
Had progressive disease while on crizotinib, as assessed by the investigator or treating physician.
History of clinically significant (as determined by the treating physician) atrial arrhythmia
Active infection > CTCAE Grade 2, that is considered clinically serious by the treating physician
Subjects with a significant history of malabsorption (e.g. celiac sprue, short bowel syndrome, or other, as determined by the treating physician) are excluded
Patients with other major medical or psychiatric illnesses which the treating physician feels could seriously compromise tolerance to this protocol
Life expectancy >= 3 months as determined by the treating physician
Recommendation to undergo concurrent chemoradiation, as determined by the treating physician
Have a plan by treating physician to receive FOLFOX or FOLFOX-Avastin standard therapy for colorectal cancer as a first-line chemotherapy treatment
Active and uncontrolled disease (other than AML) or infection as judged by the treating physician
Patients must have surgically resectable disease, in the opinion of the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Significant co-morbidity that could affect the safety or evaluability of participants as assessed by the treating physician and or principal investigator
The patient has a medical or psychiatric condition that constitutes an unacceptable risk for participation in this trial, in the judgment of the treating physician
Psychiatric or medical conditions which, in the opinion of the treating physician, would not allow the patient to undergo the proposed treatments safely
Patient must have disease that is easily accessible for a core biopsy as determined by the treating physician or study principal investigator (PI), patient must agree to the mandatory biopsies at baseline and end of cycle 2 (MTD expansion cohort only, and at the discretion of the PI/PI optional)
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment
Patients with a significant systemic illness that is not well-controlled in the opinion of the treating physician are not eligible
Tumor within the irradiated field is negatively impacting patient’s quality of life or threatening catastrophic complication if left untreated as determined by the treating physician
Active and uncontrolled disease/infection as judged by the treating physician
Patients whose MRI scan demonstrates intratumoral hemorrhage or peritumoral hemorrhage are not eligible for treatment if deemed significant by the treating physician
Any other cardiac condition, which in the opinion of the treating physician would make this protocol unreasonably hazardous for the patient
The patient's treating physician states that one of the lesions can be treated with SBRT
Stage IV disease, confirmed by biopsy or unequivocal radiographic evidence (note: staging scans are not required, but should be performed at treating physician discretion in accordance with standard guidelines)
Patients who, with their treating physician, choose to proceed with an allogeneic transplant at the time of remission will not be vaccinated and will come off study
Patient is judged to be mentally reliable to follow instructions and to keep appointments (Please note that mental reliability is not determined through any specific test rather it is ascertained by the treating physician through conversation at the time of consult)
Treating physician assesses tumor to be sufficiently distant from sensitive structures to be able to achieve greater than or equal to 66 Gray (Gy) (i.e., spinal cord tolerance respected in vertebral body metastisis
Patients must have both a disease-specialist (rheumatologist/immunologist, or neurologist) physician and a bone marrow transplant physician evaluation at the treating center before a patient is considered eligible; both specialists must agree that the patient is a candidate for transplantation and patients with systemic lupus erythematosus (SLE) and multiple sclerosis (MS) must have failed standard therapies
Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance to this protocol
Subjects older than 75 years old to be discussed with principal investigator (PI) prior to subject consent; consensus between PI and treating physician is required
Life expectancy of at least 12 weeks (3 months) as determined by the treating physician.
Subject must be deemed a suitable candidate for regorafenib as per their treating physician.
Patients who are deemed eligible for transplant by their treating physician
VS surgery determined clinically necessary by the treating physician and scheduled within 4 weeks
No prior therapy for DLBCL, except =< 1 week of corticosteroids given on an emergent basis or as a temporizing measure (pre-phase where indicated by the treating physician)
Patient not eligible for (immediate) standard induction chemotherapy based on the opinion of the treating physician and the frailty score
Note: patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator
The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
A tumor lesion that can be safely biopsied as judged by the treating oncologist and physician performing the procedure and has not been radiated
Active and uncontrolled disease/infection as judged by the treating physician
Tumor accessible for unrestricted illumination for interstitial photodynamic therapy (PDT) (accessibility as determined by the physician)
Serious underlying medical or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment; similarly, any unstable medical condition that in the opinion of the treating physician or study investigators, would interfere with determination of the study objectives
Patient with any underlying medical condition that the treating physician considers might be aggravated by treatment or which is not controlled (e.g., elevated troponin or creatinine, uncontrolled diabetes)
Known inability to undergo neoadjuvant gemcitabine and cisplatin combination treatment due to pre-existing medical conditions in the opinion of the treating physician or investigator
Active serious infection that at the discretion of treating physician makes patient ineligible for chemotherapy
Participants With AML: treatment naive or relapsed for whom experimental therapy is appropriate (as assessed by their treating physician) For Part B:
Any co-morbid condition of sufficient severity to limit full compliance with the protocol per assessment by the individual treating physician
The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
Patients whose treatment plans include continuing chemotherapy after ablation as per the treating physician
Adequate residual organ function per treating physician discretion; Note: there is no limit with regard to the number of prior therapies
Previously received and are continuing to derive clinical benefit from iniparib, as monotherapy or in combination with chemotherapy, as determined by the treating physician.
Subjects with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise compliance with this protocol
The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
Tumor accessible for unrestricted illumination for photodynamic therapy (PDT) (accessibility as determined by the physician)
Patients must have adequate hepatic, hematologic and renal functioning to be able to be administered anastrozole at the discretion of the treating physician
Patients with impaired decision making as determined by the treating physician
Have contraindications to functional testing or yoga participation according to the treating physician or the physician's designee
Physical or psychological contraindication to participation at the discretion of the treating physician
Patients identified by treating physician as being unsuitable for contact
CLINICIAN: Is the treating physician providing care to a patient enrolled to the study
Patients who have received radiation without adequate relief from metastatic bone pain as determined by the patient and treating physician
Appropriate for treatment with ADT in the opinion of the treating physician
Significant intracranial pressure as per treating physician that may require surgical intervention.
Written physician approval
Subjects with an uncontrolled, active infection; subjects with viremia (cytomegalovirus or other) may be enrolled, provided they are on active therapy and at the discretion of the treating physician
Treating oncologist consent
Painful metastases to the skull, hands, feet are not eligible treatment sites, but can be treated off study with conventional fractionation at the discretion of the treating physician
Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician)
Patients with a history of hypersensitivity to dexamethasone or having any contraindication to physical activity as determined by the treating physician
Treating oncologist consent
Treatment entails significant risk for symptomatic mucositis likely to require opioid analgesia, as per the discretion of treating physician/nurse practitioner (NP)
Permission from treating/study physician to participate in RT
Neuropathic symptoms must be related to chemotherapy (in the opinion of the treating physician).
Physically able to exercise and have physician consent from their treating physician to start a physical activity program
Approved to be contacted by the treating urologist
Patients who, in the opinion of the treating physician, have a medical condition, or currently take medications, which are felt to contraindicate safe or effective administration of the standard three drug anti-emetic regimen used in this study
Deemed disease free by the treating physician
Treating physician approval to participate in study
Deemed appropriate for treatment in the prone position by the treating physician
ONCOLOGIST: Be a physician specializing in medical oncology
Approval for participation in the trial by attending physician
Gastrointestinal disorders in the opinion of the treating physician that would impair absorption
Significantly diseased (as determined by the principal investigator [PI] or treating physician) or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
Patients who are taking medications (including minocycline) or have conditions that potentially preclude use of the study medication or intervention as determined by the treating physician
Patients continuously taking any minocycline within the last 15 days; patients who have conditions that potentially preclude use of minocycline as determined by the treating physician
Patients who are taking minocycline for other conditions, as determined by the treating physician
CLINICIAN: Is the treating physician providing care to a patient enrolled to the study
Minocycline trial only: patients who are taking medication or have conditions that potentially preclude use of minocycline, as determined by the treating physician
The patient’s current treatment plan must include an anti-emetic regimen with either ondansetron or granisetron on a scheduled basis; patients may also receive dexamethasone for antiemetic prophylaxis during the acute phase at the discretion of the treating physician; patients ? 12 years old may also receive aprepitant in conjunction with dexamethasone for antiemetic prophylaxis at the discretion of the treating physician
The opinion of the treating physician determines it is not medically safe to participate in the study
Patients will receive standard of care systemic treatment for underlying solid malignancy as deemed necessary by treating physician
Patients with any condition that precludes use of the study medication as determined by the treating physician
Patients getting radiation therapy are allowed at the discretion of the treating physician
Ability to engage safely in moderate exercise as determined by their treating physician
Clinically significant elevation of liver function tests prior to the first day of dosing (FDD) that at the discretion of the treating physician would preclude the administration of an azole antifungal
Prior malignancy in which they received any thoracic radiotherapy unless the treating physician considers it unlikely to impact the clinical outcome of the patient
Medication approval from their own physician
Significant medical or psychiatric problems which would make the subject a poor protocol candidate, in the opinion of the treating physician
Subjects must be accessible for treatment, adverse event tracking and follow-up as determined by the treating physician
For cohort A, only patients with metastatic cancer to the brain for whom their treating physician has planned to give immunotherapy as monotherapy are eligible for this study; this can be in the setting of a clinical trial or not
For cohort B, only patients with GBM for whom their treating physician has planned to give immunotherapy are eligible for this study; this can be in the setting of a clinical trial or not
Patients with intracerebral hemorrhage deemed significant by treating physician are excluded
Need to be treated with taxane containing chemotherapy as determined by their treating physician
Patients selected for Ra-223 dichloride therapy for treatment of bone metastasis by their treating physician
Good operative candidate as determined by the treating physician and multidisciplinary team
Must have an MRI scan ordered by a treating physician
For patients who do not have a tissue diagnosis:\r\n* Non-oncologic severe co-morbidities suggesting a life span of less than two years if not treated, as determined by the potential subject’s treating physician\r\n* If severe co-morbidities are present, the treating physician should indicate that a life span of 2 years is expected if treatments are effective\r\n* This exclusion is to prevent loss of the needed 2 year CT follow-up to establish a benign diagnosis for lesions lacking tissue diagnosis if extremely fragile subjects are enrolled and then experience an untimely, unrelated death
Patients being considered for RALP and pelvic lymphadenectomy with life expectancy greater than 10 years as determined by treating physician
Participants must be eligible for preoperative chemotherapy for IBC as determined by the treating physician
Subjects with known hepatic insufficiency or cirrhosis as determined by either a prior diagnosing physician or at review at initial consultation; these disease entities do not have formal associated lab values and are thus a clinical diagnosis by the prior aforementioned physician
Subject who is deemed by the treating physician to have a contraindication to definitive treatment
Physician recommendation of ADT
Patients who, with their treating physician, choose to proceed with an allogeneic transplant at the time of remission will not be eligible for randomization
Subject will not proceed with transplantation as either a decision not to proceed with transplantation has been made either on the recommendation of the treating physician or by the patient or a suitable donor could not be identified.
Stereotactic radiation treatment of stage I disease or adjuvant chemotherapy is allowed at the discretion of treating physician for the participating subject
Medical co-morbidities making surgery unsafe, as determined by the primary treating physician
Medically able to undergo primary cytoreductive surgery, at least 14 days and up to 28 days after starting study drug, as determined by treating physician
Life expectancy of >= 6 months (as determined by treating physician)
Serious underlying medical (including acute decompensated congestive heart failure) or psychiatric illnesses that would, in the opinion of the treating physician, substantially increase the risk for complications related to treatment; similarly, any unstable medical condition that, in the opinion of the treating physician or study investigators, would interfere with the study objectives
Medically able to undergo primary cytoreductive surgery, at least 7 days and up to 28 days after starting study drug, as determined by treating physician
Have the approval of their treating physician to receive the 6 week ibuprofen/placebo regimen (200 mg twice a day and doses 8 hours apart); (physician must sign eligibility checklist prior to registration)
Seeing a participating physician for less than a year and expecting to see this physician at least once in the following year
PATIENTS: A prognosis of 12 months or less based on the treating oncologist’s assessment